Genomic Biomarker Market By Product Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray Technology, Mass Spectrometry, Fluorescence In Situ Hybridization (FISH)), By Application (Cancer Diagnostics, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Personalized Medicine), By End-User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostics Laboratories, Healthcare Providers, Government Agencies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Genomic Biomarker Market was valued at USD 5.4 billion in 2024-e and will surpass USD 13.5 billion by 2030; growing at a CAGR of 14.1% during 2025 - 2030.

The genomic biomarker market plays a crucial role in advancing personalized medicine and improving disease diagnostics and therapeutic monitoring. Genomic biomarkers, which are genetic indicators of disease presence, progression, or response to treatment, have found widespread applications in oncology, cardiovascular, neurological, and infectious diseases. The market has been growing at a rapid pace due to technological advancements, increased demand for precision medicine, and the rise of early diagnosis practices. As pharmaceutical companies and healthcare providers move toward more individualized treatment strategies, genomic biomarkers are becoming essential tools for enhancing clinical outcomes.

Diagnostic Biomarkers Segment Is Largest Owing To Increased Demand for Early Disease Detection

Among the various types of genomic biomarkers, diagnostic biomarkers currently dominate the market. These biomarkers are critical in identifying the presence of diseases, particularly in the early stages, enabling timely treatment and better patient outcomes. The increasing prevalence of chronic diseases, such as cancer and cardiovascular conditions, is fueling the growth of diagnostic biomarkers. Additionally, advancements in next-generation sequencing (NGS) and PCR-based diagnostics have significantly enhanced the sensitivity and accuracy of these biomarkers. As a result, diagnostic biomarkers are being increasingly incorporated into clinical practice, supporting the global trend toward early diagnosis and preventative care.

Next-Generation Sequencing (NGS) Technology Is Fastest Growing Due To Its Precision and Efficiency

In the technology segment, next-generation sequencing (NGS) is the fastest-growing subsegment, driven by its ability to analyze the entire genome at a fraction of the cost and time required by traditional methods. NGS has revolutionized genomic research, enabling high-throughput sequencing and detailed genomic profiling, which is particularly useful for discovering novel biomarkers and understanding complex diseases like cancer. The increasing adoption of NGS in clinical diagnostics and personalized medicine is expected to propel its growth further, as it allows for precise identification of disease-causing mutations and supports the development of targeted therapies. Moreover, NGS technology is expected to play a vital role in drug development and clinical trials, where genetic information can be used to identify patient populations most likely to respond to treatment.

Cancer Diagnostics Segment Is Largest Owing To Rising Cancer Incidences Worldwide

The cancer diagnostics application segment is the largest in the genomic biomarker market due to the rising incidence of cancer globally. Cancer is one of the most common and life-threatening diseases, and genomic biomarkers are increasingly used for its diagnosis, monitoring, and personalized treatment. Biomarkers like genetic mutations, gene expression profiles, and microRNA profiles are being employed to identify cancer early, determine its type, predict treatment responses, and monitor relapse. As cancer therapies continue to evolve, with an emphasis on personalized and precision medicine, the demand for genomic biomarkers in oncology diagnostics is expected to remain strong, making this the dominant application segment.

Pharmaceutical & Biotechnology Companies Segment Is Largest Owing To Strong Investment in Drug Discovery and Development

Pharmaceutical and biotechnology companies are the largest end-user industry in the genomic biomarker market. These companies leverage genomic biomarkers extensively in drug discovery, clinical trials, and the development of targeted therapies. The rising demand for personalized medicines is driving significant investments in genomic research by pharmaceutical firms. By utilizing biomarkers to identify disease mechanisms, predict patient responses to treatments, and identify potential drug candidates, these companies are able to streamline their R&D processes and improve the efficacy of their therapies. Furthermore, collaboration between biopharmaceutical companies and diagnostic firms to co-develop companion diagnostics is contributing to the strong demand for genomic biomarkers in this sector.

North America Region Is Largest Due To Strong Healthcare Infrastructure and Research Activities

Geographically, North America is the largest market for genomic biomarkers. The region benefits from a well-established healthcare infrastructure, advanced research capabilities, and high adoption rates of advanced diagnostic technologies. The U.S. in particular has become a hub for cutting-edge genomic research, with numerous biotech and pharmaceutical companies, academic institutions, and diagnostic companies involved in biomarker discovery and application. Additionally, government initiatives, such as the U.S. Precision Medicine Initiative and the Human Genome Project, have accelerated the growth of genomic biomarkers in clinical practice. With an increasing number of cancer cases and the rising demand for personalized treatments, the North American market is expected to maintain its dominant position in the global genomic biomarker market.

Competitive Landscape: Leading Companies and Market Outlook

The genomic biomarker market is highly competitive, with several global companies leading the charge in technological innovations, biomarker discovery, and product development. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Roche Diagnostics, Illumina, and QIAGEN, among others. These companies are engaged in strategic collaborations, mergers, and acquisitions to expand their product portfolios and strengthen their position in the market. Additionally, advancements in diagnostic tools, including NGS-based platforms, and growing investments in R&D are key trends shaping the competitive landscape. As the demand for precision medicine and personalized treatments continues to rise, companies are increasingly focusing on the development of innovative genomic biomarkers that can cater to a wide range of diseases, particularly in oncology. With a focus on accelerating biomarker discovery, companies in this space are expected to drive continued growth in the genomic biomarker market

Recent Developments:

• Thermo Fisher Scientific has recently launched a new genomic testing platform aimed at enhancing cancer biomarker discovery, which integrates both genomic and proteomic data.
• Illumina completed the acquisition of Grail for a multi-billion-dollar deal aimed at accelerating its capabilities in early cancer detection through liquid biopsy technology.
• QIAGEN received regulatory approval from the FDA for its new genomic diagnostic panel designed to identify biomarkers for non-small cell lung cancer.
• Bio-Rad Laboratories launched a next-generation PCR kit focused on oncology biomarkers, improving precision in monitoring genetic mutations in cancer patients.
• Abbott Laboratories has partnered with several research institutions to develop advanced genomic biomarker solutions for personalized treatments in cardiovascular diseases.

List of Leading Companies:

• Thermo Fisher Scientific
• Agilent Technologies
• Roche Diagnostics
• Illumina, Inc.
• Bio-Rad Laboratories
• QIAGEN
• Abbott Laboratories
• PerkinElmer
• GE Healthcare
• Siemens Healthineers
• Merck KGaA
• Becton Dickinson and Company
• Bio-Techne
• Thermo Fisher Scientific
• Pacific Biosciences of California

Report Scope: